Updates are available Correction dated 2025-02-03

Article History

Received: 5 April 2024

Accepted: 9 October 2024

First Online: 29 November 2024

Change Date: 23 January 2025

Change Type: Update

Change Details: The article was revised due to retrospective open access.

Change Date: 3 February 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12325-025-03107-9

Declarations

:

: Carol Pollock reports advisory board membership for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Vifor Pharma; and speaker fees for AstraZeneca, Janssen-Cilag, Novartis, Otsuka and Vifor Pharma. Juan-Jesus Carrero reports institutional grants from Astellas, AstraZeneca and Vifor Pharma; speaker fees from AstraZeneca, Abbott and Nutricia; and consultancy for AstraZeneca and Bayer. Eiichiro Kanda is a consultant for AstraZeneca. Richard Ofori-Aseno, Hungta Chen, Juan Jose Garcia Sanchez and Surendra Pentakota are employees of and hold or may hold stock in AstraZeneca. Roberto Pecoits-Filho is an employee of Arbor Research Collaborative for Health, which receives global support for the ongoing Dialysis Outcomes and Practice Patterns Study Programs (provided without restriction on publications by a variety of funders; for details see ). Roberto Pecoits-Filho also reports: research grants from Fresenius Medical Care; nonfinancial support from Akebia, AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk and FibroGen; personal fees from Travere Therapeutics; and consulting fees from George Clinical outside the submitted work. Steven Fishbane reports research support and consulting fees from AstraZeneca; and research support from Akebia Inc., MegaPro Biomedical Co., Ltd., Ardelyx, Corvidia Therapeutics, Inc. and Cara Therapeutics. Carolyn S. P. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from NovoNordisk and Roche Diagnostics; has served as a consultant or is on the advisory board/steering committee/executive committee for Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, Cytokinetics, Darma Inc., EchoNous Inc., Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Inc., Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, NovoNordisk, Prosciento Inc., Quidel Corporation, Radcliffe Group Ltd., Recardio Inc., ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. Naoki Kashihara is a consultant for AstraZeneca, Boehringer Ingelheim, and Kyowa Hakko Kirin; and receives honoraria from Kyowa Hakko Kirin and Daiichi Sankyo. David C. Wheeler reports personal fees and nonfinancial support from AstraZeneca; and personal fees from Astellas, Bayer, Boehringer Ingelheim, GSK, Janssen, Mundipharma, Napp, Reata Pharmaceuticals, Tricida and Vifor Fresenius.

: This study was performed in accordance with ethical principles consistent with the Declaration of Helsinki, International Conference on Harmonisation, Good Clinical Practice, and the applicable legislation on noninterventional studies and observational studies. The study received central (approval numbers, Italy: 711/19; UK, REC No. 19/YH/0357; Sweden, DNR 2019–05355; Spain 2021/342; and USA, Pro00036594) and local (Japan) institutional review board ethics approval. The names of the central ethics committees that approved the study are Italy: Comitato Etico Indipendente Istituto Clinico Humanitas; Spain: Ethics Committee for Research with Drugs of Galicia; Sweden: Swedish Ethical Review Authority; UK: Health Research Authority; and USA: Advarra. A full list of study sites and their respective ethics committees is provided in Supplementary Table . All patients provided written informed consent.